India is growing in importance as a hub for biopharmaceutical manufacturing, particularly in the context of the proposed Biosecure Act in the United States. The Act aims to restrict U.S. biotech companies from working with Chinese firms, potentially driving more business towards Indian contract development and manufacturing organizations (CDMOs). A...